San Francisco, CA, United States of America

Kirk D Robarge

USPTO Granted Patents = 19 (Patent Applications = 3)

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 112(Granted Patents)

Location History:

San Franscisco, CA (US) (1997)
San Francisco, CA (US) (1996 - 2014)
South San Francisco, CA (US) (2014 - 2019)

Company Filing History:

F. Hoffmann-la Roche Ag

where one patent can have more than one assignee

Years Active: 1996-2019

Loading Chart...

19 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10519126 - Serine/threonine kinase inhibitors (2019-12-31),

2. 9708290 - Serine/threonine kinase inhibitors (2017-07-18),

3. 9388171 - Serine/threonine kinase inhibitors (2016-07-12),

4. 9259470 - Serine/threonine kinase inhibitors (2016-02-16),

5. 8828990 - N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use (2014-09-09),

6. 8697715 - Serine/threonine kinase inhibitors (2014-04-15),

7. 8486950 - Janus kinase inhibitor compounds and methods (2013-07-16),

8. 8288381 - N-9 substituted purine compounds, compositions and methods of use (2012-10-16),

9. 8101610 - Bisamide inhibitors of hedgehog signaling (2012-01-24),

10. 7109326 - Halo-alkoxycarbonyl prodrugs (2006-09-19),

11. 6919369 - Serine protease inhibitors (2005-07-19),

12. 6472393 - Serine protease inhibitors (2002-10-29),

13. 5716951 - Tricyclic inhibitors of the vitronectin receptor (1998-02-10),

14. 5705890 - Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor (1998-01-06),

15. 5674865 - Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b (1997-10-07),

Title: Kirk D. Robarge: Innovator in Serine/Threonine Kinase Inhibition

Introduction

Kirk D. Robarge is a prominent inventor based in San Francisco, CA, with an impressive portfolio of 19 patents. His innovative work primarily focuses on serine/threonine kinase inhibitors, which hold significant potential for treating various diseases.

Latest Patents

Robarge's latest patents include compounds of Formula I, as well as their stereoisomers, tautomers, prodrugs, and pharmaceutically acceptable salts. These compounds have been identified as useful for the treatment of hyperproliferative, pain, and inflammatory diseases. The methods outlined in these patents describe their application in in vitro, in situ, and in vivo diagnostics and treatment of associated pathological conditions in mammalian cells.

Career Highlights

Throughout his career, Kirk D. Robarge has made substantial contributions to the pharmaceutical and biotechnology sectors. He has worked with notable companies, including Genentech, Inc. and Array Biopharma Inc., where he utilized his expertise to drive research and development efforts in drug innovation.

Collaborations

Robarge has collaborated with several esteemed colleagues, including Aihe Zhou and Brent K. Blackburn. These partnerships have fostered an environment of innovation, leading to advancements in therapeutic compounds and their applications.

Conclusion

Kirk D. Robarge's advancements in serine/threonine kinase inhibition reflect his dedication to addressing significant medical challenges. His ongoing work continues to enhance the understanding and development of effective treatments for hyperproliferative, pain, and inflammatory diseases, positioning him as a key figure in the realm of biotechnology.

This text is generated by artificial intelligence and may not be accurate.